Product Comparison


  Sanofi Pasteur 49281071910 Seqirus USA Inc 70461041910 Seqirus USA Inc 70461031903 Seqirus USA Inc 33332041910 Seqirus USA Inc 33332031901
McKesson # 1120530 1121575 1121577 1121562 1121565
Description Flublok® Quadrivalent 2019 - 2020 Flu Vaccine 180 mcg / 0.5 mL Indicated For People 18 Years and Above Prefilled Syringe 0.5 mL Flucelvax® Quadrivalent 2019 - 2020 Flu Vaccine 60 mcg / 0.5 mL Indicated For People 4 Years of Age and Above Multiple Dose Vial 5 mL Flucelvax® Quadrivalent 2019 - 2020 Flu Vaccine 60 mcg / 0.5 mL Indicated For People 4 Years of Age and Above Prefilled Syringe 0.5 mL Afluria® Quadrivalent 2019 - 2020 Flu Vaccine 60 mcg / 0.5 mL Indicated for People 6 Months of Age and Above Multiple Dose Vial 5 mL Afluria® Quadrivalent 2019 - 2020 Flu Vaccine 60 mcg / 0.5 mL Indicated For People 3 Years of Age and Above Prefilled Syringe 0.5 mL
Manufacturer # 4928107191070461041910704610319033333204191033332031901
Brand Flublok® Quadrivalent 2019 - 2020Flucelvax® Quadrivalent 2019 - 2020Flucelvax® Quadrivalent 2019 - 2020Afluria® Quadrivalent 2019 - 2020Afluria® Quadrivalent 2019 - 2020
Manufacturer Sanofi PasteurSeqirus USA IncSeqirus USA IncSeqirus USA IncSeqirus USA Inc
Invoice FLUBLOK 2019 QUAD, SYR 0.5ML (10DOSE/BX)FLUCELVAX 2019, QUAD MDV 5ML (10DOSE/VL)FLUCELVAX 2019, QUAD SYR 0.5ML(10DOSE/BX)AFLURIA 2019, QUAD MDV 5ML (10DOSE/VL)AFLURIA 2019, QUAD SYR 0.5ML (10DOSE/BX)
    Log In to Order   Log In to Order   Log In to Order   Log In to Order   Log In to Order

Comparison

Container Type Prefilled SyringeMultiple Dose VialPrefilled SyringeMultiple Dose VialPrefilled Syringe
Country of Origin UnknownUnited StatesUnited StatesAustraliaAustralia
NDC Number 4928107191070461041910704610319033333204191033332031901
Strength 180 mcg / 0.5 mL60 mcg / 0.5 mL60 mcg / 0.5 mL60 mcg / 0.5 mL60 mcg / 0.5 mL
User Indicated For People 18 Years and AboveIndicated For People 4 Years of Age and AboveIndicated For People 4 Years of Age and AboveIndicated For People 6 Months of Age and AboveIndicated For People 3 Years of Age and Above
Volume 0.5 mL5 mL0.5 mL5 mL0.5 mL
Application Flu VaccineFlu VaccineFlu VaccineFlu VaccineFlu Vaccine
Dosage Form InjectionInjectionInjectionInjectionInjection
Storage Requirements Requires RefrigerationRequires RefrigerationRequires RefrigerationRequires RefrigerationRequires Refrigeration
Type IntramuscularIntramuscularIntramuscularIntramuscularIntramuscular
UNSPSC Code 5120160851201608512016085120160851201608
Features and Benefits
  • Flublok Quadrivalent is a vaccine indicated for active immunization against disease caused by influenza virus subtypes A and type B contained in the vaccine
  • Flublok Quadrivalent is approved for use in persons 18 years of age and older
  • Flublok contains no egg proteins, antibiotics, or preservatives
  • Flublok Quadrivalent is standardized according to United States Public Health Service (USPHS) requirements. For the 2019-2020 influenza season it is formulated to contain 180 mcg HA per 0.5 mL dose, with 45 mcg HA of each of the following 4 influenza virus strains: A/Brisbane/02/2018 (H1N1), A/Kansas/14/2017 (H3N2), B/Maryland/15/2016 (a B/Colorado/6/2017-like virus) and B/Phuket/3073/2013.
  • FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine
  • FLUCELVAX is approved for use in persons 4 years of age and older
  • FLUCELVAX QUADRIVALENT 5 mL multi-dose vial formulation contains no antibiotics
  • FLUCELVAX QUADRIVALENT is standardized according to United States Public Health Service requirements for the 2019-2020 influenza season and is formulated to contain a total of 60 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA of each of the following four influenza strains:
  • A/Idaho/07/2018 (an A/Brisbane/02/2018 (H1N1)pdm09-like virus), A/Indiana/08/2018 (an A/Kansas/14/2017 (H3N2)-like virus), B/Iowa/06/2017 (a B/Colorado/06/2017-like virus), B/Singapore/INFTT-16-0610/2016 (a B/Phuket/3073/2013-like virus)
  • FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine
  • FLUCELVAX is approved for use in persons 4 years of age and older
  • FLUCELVAX QUADRIVALENT 0.5 mL pre-filled syringes contain no preservative or antibiotics
  • FLUCELVAX QUADRIVALENT is standardized according to United States Public Health Service requirements for the 2019-2020 influenza season and is formulated to contain a total of 60 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA of each of the following four influenza strains:
  • A/Idaho/07/2018 (an A/Brisbane/02/2018 (H1N1)pdm09-like virus), A/Indiana/08/2018 (an A/Kansas/14/2017 (H3N2)-like virus), B/Iowa/06/2017 (a B/Colorado/06/2017-like virus), B/Singapore/INFTT-16-0610/2016 (a B/Phuket/3073/2013-like virus)
  • AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
  • AFLURIA QUADRIVALENT is approved for use in persons 6 Months and older
  • The multi-dose presentation contains thimerosal added as a preservative; each 0.5 mL dose contains 24.5 mcg of mercury
  • AFLURIA QUADRIVALENT is standardized according to USPHS requirements for the 2019-2020 influenza season and is formulated to contain 60 mcg hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA for each of the four influenza strains recommended for the 2019-2020 Northern Hemisphere influenza season:
  • A/Brisbane/02/2018 (IVR-190) (an A/Brisbane/02/2018 (H1N1)pdm09 – like virus), A/Kansas/14/2017 (X-327) (an A/Kansas/14/2017 (H3N2) – like virus), B/Maryland/15/2016 (a B/Colorado/06/2017 – like virus) and B/Phuket/3073/2013 BVR-1B (a B/Phuket/3073/2013 – like virus). A 0.25 mL dose contains 7.5 mcg HA of each of the same four influenza strains.
  • AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
  • AFLURIA QUADRIVALENT is approved for use in persons 3 Years of age and older
  • AFLURIA QUADRIVALENT is standardized according to USPHS requirements for the 2019-2020 influenza season and is formulated to contain 60 mcg hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA for each of the four influenza strains recommended for the 2019-2020 Northern Hemisphere influenza season:
  • A/Brisbane/02/2018 (IVR-190) (an A/Brisbane/02/2018 (H1N1)pdm09 – like virus), A/Kansas/14/2017 (X-327) (an A/Kansas/14/2017 (H3N2) – like virus), B/Maryland/15/2016 (a B/Colorado/06/2017 – like virus) and B/Phuket/3073/2013 BVR-1B (a B/Phuket/3073/2013 – like virus). A 0.25 mL dose contains 7.5 mcg HA of each of the same four influenza strains.